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Nodal and Activin belong to the TGF-b superfamily
and are important regulators of embryonic stem cell
fate. Here we investigated whether Nodal and Activin
regulate self-renewal of pancreatic cancer stemcells.
Nodal and Activin were hardly detectable in more
differentiated pancreatic cancer cells, while cancer
stem cells and stroma-derived pancreatic stellate
cells markedly overexpressed Nodal and Activin,
but not TGF-b. Knockdown or pharmacological inhi-
bition of the Nodal/Activin receptor Alk4/7 in cancer
stem cells virtually abrogated their self-renewal
capacity and in vivo tumorigenicity, and reversed
the resistance of orthotopically engrafted cancer
stem cells to gemcitabine. However, engrafted
primary human pancreatic cancer tissue with
a substantial stroma showed no response due to
limited drugdelivery. The addition of a stroma-target-
ing hedgehog pathway inhibitor enhanced delivery of
the Nodal/Activin inhibitor and translated into long-
term, progression-free survival. Therefore, inhibition
of the Alk4/7 pathway, if combined with hedgehog
pathway inhibitionandgemcitabine,providesa thera-
peutic strategy for targeting cancer stem cells.
INTRODUCTION
Although pancreatic ductal adenocarcinoma has become the
subject of increasing research efforts over the past decades,
poor response to therapy with subsequent dismal survival hasCelremained the hallmark of this disease. Recent evidence from
our and other laboratories suggests that pancreatic carcinomas
harbor a distinct subpopulation of putative cancer stem cells
(CSCs) defined by their self-renewal capacity, differentiation
ability, exclusive in vivo tumorigenicity (Hermann et al., 2007;
Li et al., 2007), and ability to drive metastasis (Hermann et al.,
2008). Most importantly, CSCs have also been proposed as
the major source of resistance toward conventional chemo-
therapy and radiotherapy (Bar et al., 2007; Hermann et al.,
2007; Mueller et al., 2009). Therefore, novel therapies capable
of eliminating CSCs while leaving normal stem cells unaffected
are urgently needed.
Members of the TGF-b family, namely Bone Morphogenic
Proteins (BMPs), TGF-b, and Nodal/Activin, exert multiple, and
sometimes opposing, effects on a variety of cell types depending
on the cellular context, including the stage of the disease, the
local environment, and the identity and the dosage of the ligand
(Massague´, 2008; Watabe and Miyazono, 2009). Nodal and Ac-
tivin as secreted proteins are expressed during embryonic devel-
opment and are implicated in developmental events such as
mesoderm formation and left-right axis specification. Moreover,
they were shown to be essential for human embryonic stem cell
(ESC)maintenance (Vallier et al., 2005; Xiao et al., 2006), but their
role in cancer still remains poorly defined. Nodal and Activin bind
to their common receptors, the Activin-like (Alk) type I receptors
Alk4 and 7, while Cripto-1 constitutes an important coreceptor
for Nodal signaling only (Strizzi et al., 2005). Recently, Nodal
signaling was linked to a more aggressive phenotype in mela-
noma and breast cancer cells (Topczewska et al., 2006). Further-
more, inhibition of Nodal signaling has been shown to reduce
tumorigenicity in melanoma cell lines, suggesting a potential
role in tumor-initiating cells (Postovit et al., 2008). Encouraged
by these reports, we investigated the role of the Nodal/Activin
signaling cascade in the tumorigenic stem cell compartment ofl Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Inc. 433
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Figure 1. Sphere-Derived Pancreatic CSCs Express Pluripotency Markers
(A) Morphology of pancreatic cancer cells derived from xenografts and freshly isolated human tissue grown as monolayers or spheres.
(B) Flow cytometry analysis for CD44, CD133, CXCR4, SSEA-4, and SSEA-1 as cancer stem cell markers in spheres as compared with adherent cells from A6L or
185 tumors.
(C) qPCR analysis of pluripotency-associated genes in adherent cells versus spheres. Data are normalized to GAPDH expression and are presented as fold
change in gene expression relative to adherent cells.
(D) Western blot analysis of Nanog, Oct4a, and GAPDH in spheres as compared with adherent cells. Nanog promoter RFP reporter construct illustrates the
presence of single Nanog promoter+ cells in spheres.
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the successful elimination of pancreatic CSCs as the root of
this deadly disease.RESULTS
Pancreatic CSCs Express Pluripotency-Associated
Markers
We have shown that primary pancreatic CSCs can be enriched
in vitro as anchorage-independent spherical colonies termed
spheres (Hermann et al., 2007). These spheres are composed
of a small number of cells with stem cell-like properties including
the ability to form secondary spheres as well as more differenti-
ated progenies. Recently, we also reported the enrichment of
pancreatic CSCs within the CD133+-expressing cell population
as assessed by flow cytometry (Hermann et al., 2007). Therefore,434 Cell Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Incfor the present studies, we used these two supplementary
methods for studying pancreatic CSCs.
A total number of eight human pancreatic adenocarcinoma
xenografts were used, with A6L, 185, JH051, 247, and 198 being
described earlier as primary tumors or tumor-derived primary
cell lines (Jones et al., 2008; Rubio-Viqueira et al., 2006), and
with 265, 286, and 354 produced by the same technique. Impor-
tantly, all cells for in vitro experiments were freshly isolated from
early passage xenografts. Isolated cells from these xenografts
were cultured as adherent cells (monolayer) or anchorage-inde-
pendent spheres at low passages (Figure 1A). Moreover, three
established pancreatic cancer cell lines (L3.6pl, MiaPaCa2,
and Panc1) were used. Cells were phenotyped by flow cytometry
for the expression of CD133, CD44, CXCR4, SSEA-4, and SSEA-
1. As previously reported, spheres are enriched in CD133+ cells,
as well as several other markers that have been associated with
a CSC phenotype such as CXCR4, SSEA-4, and SSEA-1, as.
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Misteli, 2011). In contrast, cells expressing adhesion molecules
such as CD44 (Figure 1B) and EpCAM (data not shown) were
not consistently enriched in sphere culture, mostly likely reflect-
ing anchorage-independent culture conditions, and were there-
fore not linked to a CSC phenotype in cultured cells (Figure S1A
available online).
Next, the expression of pluripotency-associated genes
(Nanog, Oct3/4, Stat3, Klf4, and Sox2) was determined by real-
time PCR. Expression of pluripotency-associated genes was
significantly higher in first generation sphere culture (d7) versus
70% confluent monolayer culture (Figure 1C). Intriguingly, the
expression levels observed for pancreatic spheres were compa-
rable to those of human ESCs (data not shown). Expression of
protein levels was validated for Oct4a and Nanog by western
blotting and using a Nanog promoter reporter construct
(Figure 1D).
Components of the Nodal/Activin Signaling Cascade
Are Overexpressed in Primary Pancreatic CSCs
Because theNodal/Activin pathway is reportedly inactive in adult
tissue (Hendrix et al., 2007; Topczewska et al., 2006), we deter-
mined whether this pathway is reactivated in pancreatic cancer
(stem) cells by assessing mRNA expression for its components,
namely Nodal, Cripto-1, FoxH1, Smad2, Smad4, Gdf1, Activin,
and Alk4. Real-time PCR demonstrated that Nodal/Activin
signaling-related genes are significantly overexpressed in first-
passage spheres as compared with those in adherent cells,
although marked differences in mRNA expression between the
various tumorscanbenoted (Figure2A). Interestingly, theexpres-
sion further and strongly increased in second-passage spheres
(Figure 2B). Western blot analysis demonstrated that Nodal is
consistently and strongly overexpressed in spheres as compared
with adherent cells on the protein level (Figure 2C), and that Alk4+
as well as Cripto+ cells are also enriched in sphere culture as
determined by flow cytometry (Figure S1B). In contrast, mRNA
levels for TGF-b1, TGF-b type I receptor/Alk5, and TGF-b type II
receptor did not differ between sphere-derived cells and
adherent cells, while flow cytometry revealed even decreased
numbers of Alk5+ cells in spheres (Figures S1B and S1C).
Most importantly, spheres showed enhanced expression of all
essential components of the Nodal pathway including phosphor-
ylation of Smad2. This allows its association with Smad4 fol-
lowed by subsequent translocation to the nucleus to regulate
target gene expression, suggesting that the Nodal signaling
pathway is operational (Figure 2C). Nodal was hardly detectable
in adherent cells by immunohistochemistry, while sphere-
derived cells displayed strong cytoplasmic and membranous
Nodal protein expression (Figure 2D). Data in established
pancreatic cancer cell lines also showed increased expression
of Nodal and some of its pathway components in sphere-derived
cells, although differences were less pronounced as compared
with primary cells, with no difference for the TGF-b signaling
pathway (Figures S1D and S1E). We next validated our sphere-
based in vitro data using magnetic activated cell sorting
(MACS) of CD133+ cells from freshly digested human pancreatic
tumor xenografts (185, 198, and 354). Flow cytometry showed
good depletion for CD133+ cells in the CD133 population and
revealed enrichment to 75% in the CD133+ population (Fig-Celure 2E). Real-time PCR analysis showed increased expression
of Nodal-signaling-associated genes. Specifically, Nodal,
Cripto-1, Cripto-3, Activin, and Alk4 were overexpressed in
CD133+ cells as compared with CD133 cells (Figure 2F). Impor-
tantly, Nodal expression at the mRNA and protein level was not
detectable in normal pancreatic tissue (Figure 2G), but Nodal
was highly expressed in pancreatic cancer tissue with strong
upregulation during development and progression of primary
pancreatic ductal adenocarcinoma as shown in representative
tissue microarray samples (Figures 2G and 2H). Because Nodal
expression has recently been shown to be reactivated in breast
cancer tissue (Topczewska et al., 2006), we also investigated the
modulation of Nodal and its pathway components in putative
MCF7 breast cancer stem cells (Engelmann et al., 2008). Consis-
tent with the data obtained for pancreatic cancer cells, Nodal, its
cofactor Cripto-1, and several pluripotency-associated markers
were overexpressed in MCF7-derived spheres as compared
with adherent cultures (Figures S1F and S1G). These results indi-
cate that enhanced Nodal expression in the CSC fraction is not
restricted to pancreatic cancer.
Nodal/Activin Signaling Is Functionally Active
in Pancreatic CSCs
Nodal andActivin aresecretedproteins that exert their functionby
binding to and joining the cell surface receptors Alk4 and Alk7 to
form a tertiary ligand-receptor complex that leads to the phos-
phorylation of Smad2 or Smad3 as intracellular effectors and
the subsequent regulation of cell functions. Todeterminewhether
rNodal and rActivin, respectively, are capable of activating this
signaling cascade, we starved human primary sphere-derived
CSCs as illustrated in Figure 3A. Cells were then treated with
recombinant protein in the presence or absence of the Alk4/7
inhibitor SB431542 or LY2157299 (specific inhibitor of Alk5). After
30 min of stimulation, phosphorylation of Smad2 and expression
of Nanog, Oct3/4, Klf4, Sox2, and Stat3 were determined. Puta-
tive cytotoxicity of the utilized inhibitors was excluded by expo-
sure of the cells to the inhibitors for 24 hr followed by DAPI/
Annexin V staining (Figure 3B). rNodal/rActivin strongly induced
phosphorylation of Smad2, while pretreatment with SB431542
partially abrogated Smad2 phosphorylation after stimulation
with rNodal (Figures 3C and 3D). In contrast, TGF-b1 did not
induce phosphorylation of Smad2 in sphere-derived cells; nor
did theAlk5 inhibitor LY2157299 result in a reducedSmad2phos-
phorylation. These results suggest that only Nodal andActivin are
capable of activating the Alk4/7 signaling cascade by Smad2
phosphorylation in pancreatic CSCs.
Nodal and Activin Drive Self-Renewal
of Pancreatic CSCs
To characterize the biological effects of Nodal and Activin on
human pancreatic CSCs, we first examined whether Nodal is
capable of enhancing colony formation and self-renewal
capacity of pancreatic CSCs. In the sphere formation assay,
single cells in suspension were treated with rNodal, rActivin,
rTGF-b1, rLefty (endogenous direct inhibitor of Nodal), the
Alk4/7 inhibitor SB431542, the specific Alk5 inhibitor
LY2157299, and TGF-b receptor II neutralizing antibodies.
After 7 days, treatment with rNodal increased the number of
spheres as compared with control cells (Figure 4A). In contrast,l Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Inc. 435
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Figure 3. Nodal Signaling Is Functionally Active in Pancreatic CSCs
(A) Schematic illustration of Smad2 phosphorylation assay: cells were kept in basic sphere medium for 3 hr and stimulated for another 30 min with rNodal or
rActivin alone or in combination with SB431542. After stimulation molecular and histological analyses were performed.
(B) Cell viability was determined by flow cytometry using DAPI/Annexin V.
(C) Western blotting for pSmad2 and Smad2 after stimulation with rNodal or rActivin alone or in combination with SB431542.
(D) Immunocytochemistry for pSmad2 and Nodal in A6L cells after stimulation with rNodal.
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sphere formation for all tested cells, but in long-term experi-
ments, it did enhance the number of cells with active Nanog
promoters in sphere cultures to the same extent as Nodal (Fig-
ure 4B). The diverse stimulatory effects of rNodal are most likely
related to varying levels of endogenous Nodal expression in
sphere-forming cells, because pretreatment with the Nodal-
specific inhibitor rLefty or the less specific Alk4/7 inhibitor
SB431542 dose-dependently (10, 20, and 40 mM) blocked
sphere formation, whereas this was not the case in untreated
cells (Figure 4A). Consistently, rNodal treatment resulted in the
formation of more and larger colonies as compared with control,
as determined by a soft agar assay (Figure S2). These dataFigure 2. Components of the Nodal/Activin Signaling Pathway Are Ove
qPCR analysis of Nodal-signaling-associated genes in adherent cells versus sp
expression andpresentedas fold change in geneexpression relative to adherent ce
adherent cells versus spheres. Parallel GAPDH immunoblotting was performed an
EpCAM (green), Nodal (red), and nuclei (blue) of adherent cells and spheres. (E) C
cytometry usingCD133/2. (F) qPCRanalysis forNodal-signaling-associated genes
analysis for Nodal and Activin in normal pancreatic tissue from healthy donors (M
histochemistry for Nodal (brown) in tissue sections from patients with PanIN-I to
Celfurther corroborate the crucial importance of this pathway in
the self-renewal capacity of pancreatic CSCs. In contrast,
neither the Alk5 inhibitor LY2157299 nor TGF-b receptor II
neutralizing antibodies resulted in significant changes in
sphere-forming capacity (Figure 4A), suggesting that TGF-b
signaling is not relevant for the self-renewal capacity of CSCs.
Next, we investigated the role of the TGF-b family members in
the invasive capacity of pancreatic CSCs. A Matrigel-coated,
modified Boyden chamber was used to quantitatively evaluate
cell invasion. As shown in Figure 4C, the percentage of migrated
cells increased significantly after stimulation with rNodal,
rActivin, and TGF-b1. Inhibition of Alk4/7 by SB431542 as well
as inhibition of Alk5 by SB505124 or the more specificrexpressed in Pancreatic CSCs
heres (s) in first (A) and second passage (B). Data are normalized to GAPDH
lls. (C)Western blot analysis forNodal, Smad4, pSmad2, andSmad2proteins in
d signal quantificationwas performed by densitometry. (D) Confocal images for
D133 MACS of fresh tumor-derived cancer cells. Purity was validated by flow
inCD133+ cells versusCD133cells. Data are normalized toGAPDH. (G) qPCR
722 and M723) and pancreatic ductal adenocarcinoma (PDAC). (H) Immuno-
PanIN-III lesions and three different patients with PDAC. See also Figure S1.
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Figure 4. Pharmacological Inhibition of the Nodal/Activin or TGF-b Pathway
(A) Sphere formation capacity of 185 (top panel) and A6L (bottom panel) cells after treatment with the depicted combinations and concentrations of agonists and
antagonists of the Nodal/Activin and TGF-b pathways.
(B) A Nanog reporter construct expressing RFP was used to detect Nanog promoter+ cells (red). Cells were treated with vehicle, rNodal, or rActivin.
(C) Invasion of sphere-derived 185 (top panel) and A6L (bottom panel) cells after treatment as depicted.
See also Figure S2.
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Figure 5. Genetic Targeting of the Nodal/Activin or TGF-b Pathway
(A) Lentivirally transduced cell cultures were sorted by FACS to highest purity based on GFP expression. Comparison of sphere formation capacity (upper
panel), in vivo tumorigenicity (lower panel, left), and CD133 content of harvested tumors (lower panel, right) after lentiviral delivery of scrambled or Alk4 shRNA
is shown.
(B) As in (A), but with Alk5 knockdown.
(C) Lentivirally transduced cell cultures were sorted by FACS to highest purity based on GFP expression. Comparison of sphere formation capacity (upper panel)
and in vivo tumorigenicity (lower panel) after lentiviral delivery of scrambled or Nodal shRNA is shown.
(D) Lentivirally transduced cell cultures were selected using puromycin resistance. Comparison of sphere formation capacity (upper panel, left), response to
SB431542 (upper panel, right), and in vivo tumorigenicity (lower panel) after lentiviral delivery of scrambled or Smad4 shRNA is shown.
See also Figure S3.
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invasiveness of pretreated CSCs. These data indicate that
pancreatic CSCs are capable of responding to TGF-b1 by
enhanced invasiveness, most likely via Smad2-independent
mechanisms (Zhang, 2009).
Finally, the above findings were validated using specific
genetic targeting of Alk4, Alk5,Nodal, and Smad4 using lentiviral
delivery of specific shRNA (Table S2 available online). Cells were
either selected by FACS for GFP (Alk4, Alk5, Nodal) (Figures
S3A–S3C) or by using puromycin resistance (Smad4) (Fig-
ure S3D). Knockdown of Alk4, which was validated by reduced
surface expression of Alk4 as assessed by flow cytometry (Fig-
ure S3A), resulted in a significant reduction of sphere formation
capacity and, most importantly, drastically reduced in vivo
tumorigenicity (Figure 5A). In those few and diminutive tumors
that actually formed, CD133+ cells were undetectable. In
contrast, knockdown of Alk5, also validated by reduced surface
expression of Alk5 (Figure S3B), neither affected sphere forma-Celtion capacity nor resulted in reduced in vivo tumorigenicity (Fig-
ure 5B). Consistently, the content of CD133+ cells was not
changed as compared with that of scrambled control. Impor-
tantly, population doubling of adherent cells was not significantly
altered by either knockdown, indicating that these differences
were not related to changes in proliferation rate (Figures S3A
and S3B). Knockdown of Nodal also resulted in significantly
lower sphere formation capacity (Figure 5C, Figure S3C). The
strong knockdown of Nodal translated into significantly reduced
in vivo tumorigenicity. Finally, knockdown of Smad4, a crucial
component of the canonical Alk4/7 signaling cascade, led to
a significant reduction in sphere formation capacity (Figure 5D,
Figure S3D). Intriguingly, the Smad4 knockdown translated
into reduced in vivo tumorigenicity to a level that was compa-
rable to inhibition of sphere formation and can be rationalized
by downstream inhibition of the Nodal/Activin pathway. Indeed,
while cells with scrambled shRNA strongly responded to
SB431542, cells with knockdown for Smad4 virtually lostl Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Inc. 439
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capacity (Figure 5D).
The observation that knockdown of Nodal resulted in a less
pronounced reduction of in vivo tumorigenicity despite virtually
complete knockdown of Nodal and strong inhibition of in vitro
sphere formation suggests alternative sources for Nodal and/or
Activin that may partially overcome the knockdown of Nodal in
pancreatic CSCs in vivo. Indeed, we found robust expression
of Nodal and Activin in human pancreatic stellate cells (PSCs)
as an important stromal component of the pancreas (Jesnowski
et al., 2005; Ohnishi et al., 2003) (Figure S4A). Sphere formation
and invasion of pancreatic CSCs were significantly enhanced by
PSC-conditioned medium, an effect that was abrogated by
pretreatment with the Alk4/7 inhibitor SB431542 (Figures S4B
and S4C). Together with the findings that knockdown of Nodal
did translate into reduced sphere formation in vitro, but only
moderately reduced tumorigenicity in vivo, while knockdown of
Alk4 resulted in strong reduction of both endpoints, we conclude
that in vivo CSCs are most likely stimulated in both an autocrine
and a paracrine fashion by the stromal compartment.
Nodal Inhibition Chemosensitizes Pancreatic CSCs
to Chemotherapy
Pancreatic CSCs are inherently resistant to chemotherapy,
resulting in relative enrichment for CSCs in adherent culture as
evidenced by flow cytometry (Figure 6A) and an increase in
Nodal expression (Figure 6B). Effects were more pronounced
in CSC-enriched sphere cultures (Figure 6C). Intriguingly, using
CD133 expression as readout for CSC content, we observed
a virtually complete elimination of CSCs by inhibiting the
Nodal/Activin pathway (Figure 6D), while population doubling
was not affected (data not shown). This effect was most
consistent in the presence of gemcitabine. These data were
validated in freshly isolated patient-derived pancreatic cancer
cells (Figure 6E).
For the subsequent investigation of in vivo tumorigenicity of
pretreated cells as the most important endpoint, identical
numbers of L3.6pl pancreatic cancer cells were exposed to
gemcitabine alone, SB431542 alone, or both agents. All
surviving cells were orthotopically implanted into the pancreas
of immunocompromised mice. No further in vivo treatment was
administered. Tumorigenicity was determined by noninvasive
PET scan imaging on day 32 and macroscopic and microscopic
evaluation on day 35. Importantly, only combination therapy was
capable of eliminating in vivo tumorigenicity (Figures S5A–S5C).
Mechanistically, we could show that despite a marked decrease
in CD133 content following 4 days of treatment with SB431542
alone, the CD133+ population replenished within 48 hr after with-
drawal of treatment.When cells were treatedwith SB431542 and
gemcitabine, however, the CD133+ population was irreversibly
eliminated (Figure S5D). To further elucidate the mechanism of
this finding, we performed cell cycle analyses using BrdU. Treat-
ment with SB431542 alone did not affect the percentage of
CD133+ cells in S phase, nor did it increase the percentage
of apoptotic CD133+ cells, while the addition of gemcitabine
resulted in a 3-fold increase in apoptotic CD133+ cells and virtu-
ally complete elimination of cells in S phase (Figure S5E). These
findings indicate that SB431542 is capable of reversing the
chemoresistance of the tumorigenic CSC population, most likely440 Cell Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Incby (reversibly) driving them into amore differentiated state as evi-
denced by temporary loss of CD133.
Nodal/Activin Inhibition in Established Pancreatic
Cancers
Based on these promising findings, we then investigatedwhether
inhibition of Nodal/Activin by SB431542 translates into increased
progression-free survival in pre-established pancreatic cancers.
Because only the combination pretreatment with gemcitabine re-
sulted in loss of tumorigenicity in vivo, we focused on this treat-
ment regimen.Xenograftswereestablishedbyorthotopic implan-
tation of L3.6pl cells into athymicmice and treatment was started
1 week after injection. The detailed experimental setup is de-
picted inFigure 7A.Harvestingof some tumorsafter the last round
of SB431542 administration revealed efficient in vivo targeting of
the Nodal/Activin pathway with subsequent downregulation of
Nodal (Figures S6A–S6D). Tumor growth was assessed on day
42 by palpation and confirmed by magnetic resonance imaging
(MRI) (Figure 7B). No tumors were detectable in mice receiving
combination therapy, so the study was continued until day 100
to monitor progression/putative relapse of disease. Over time,
control animals bore large, life-limiting tumors and succumbed
within 40 days after tumor implantation (median survival time:
32 days). Gemcitabine alone significantly prolonged survival
due to inhibition of tumor growth, but all animals showedprogres-
sive disease with median survival still severely limited with
54 days. For the combination of SB431542 and gemcitabine,
long-term survival was significantly better compared with gemci-
tabine alone, with 100% survival at day 100 (Figure 7C).
Next, we investigated the effects of SB431542 in primary
human pancreatic cancer tissue xenografts as the ultimate
preclinical setting (see study design in Figure 7D). In contrast to
the above findings for implantation of cancer cells, the addition
of SB431542 to gemcitabine treatment did not result in a deceler-
ation of growth of primary tumor tissue (Figure 7E). During long-
term follow-up, it was only when gemcitabine was already with-
drawn that tumor growth eventually started to slow down, as
compared with tumors treated with gemcitabine alone, while the
latter actually reaccelerated ingrowth. Thisdifference in response
to gemcitabine withdrawal resulted in a modest, but significantly
reduced, tumor burden at the 100 day follow-up point.
Based on this rather disappointing outcome and stimulated by
data from Olive et al. (2009), we hypothesized that this modest
treatment effect could be attributed to poor drug delivery in
stroma-rich primary pancreatic cancer tissue. Indeed, mass
spectrometry analysis revealed that SB431542 was hardly
detectable in tumor-bearing mice after 2 weeks of treatment
(Figure S6E). Intriguingly, the addition of the Smoothened inhib-
itor CUR199691 (CUR) for targeting the hedgehog pathway in
stromal cells drastically improved drug delivery by 10-fold.
Therefore, we next tested a triple combination therapy (gemcita-
bine, SB431542, and CUR), which translated into immediate
inhibition of tumor progression and eventually translated into
long-term stable disease at 100-day follow-up (Figures 7E and
7F and Figure S7A). Histological evaluation of the tumors ex-
planted by the end of the study confirmed a marked depletion
of tumor stroma in the triple therapy group, as well as a higher
grade of differentiation, although the later changes were of
a more subtle nature (Figure 7F). Cells isolated from harvested.
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Figure 6. Nodal Inhibition Targets CD133+ CSCs
(A) Flow cytometry for CD44 and CD133 in A6L and 185 adherent cells untreated or treated with gemcitabine (GEM). qPCR analysis forNodal,Nanog, andOct3/4
genes in A6L and 185 adherent cells (B) or spheres (C) untreated or treatedwith GEM is shown. Data are normalized for GAPDH expression. (D) Flow cytometry for
CD133 expression in L3.6pl cells untreated or treated as indicated (left panel). Quantification of CD133 expression in respective groups, with n = 3 (right panel), is
shown; data are mean ± SEM, nR 3. (E) Flow cytometry for CD133 in freshly isolated primary human pancreatic cancer cells treated with GEM in the presence or
absence of SB431542. See also Figure S4.
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sphere-forming capacity as opposed to cells isolated from
tumors treated with gemcitabine plus SB431542, which already
showed a significant reduction in sphere-forming capacity (Fig-
ure 7G, left panel). Most intriguingly, however, cells derived
from tumors treated with triple therapy had virtually lost their
sphere-forming capacity. Consistent patterns were observed
for phenotyping of the cells using flow cytometry. CD133+ or
CD133+/CD44+ cells were significantly reduced in the group
receiving triple combination therapy (Figure 7G, right panel).
Consistently, administration of triple therapy to another tumor
(JH051) resulted in similar treatment response. Taken together,
these data demonstrate that triple therapy is capable of elimi-
nating tumor-promoting pancreatic CSCs in vivo, leading to
long-term progression-free survival.
DISCUSSION
Patients with pancreatic ductal adenocarcinoma are still
suffering from a devastating prognosis, which can be at leastCelpartially rationalized by the observation that the standard
chemotherapeutic agent gemcitabine is not capable of elimi-
nating CSCs. Indeed, gemcitabine rather leads to a relative
increase in the number of CSCs, indicating a preferential target-
ing of more differentiated and rapidly proliferating cancer cells.
The restricted elimination of the more differentiated cancer cells,
even if associated with significant tumor size reduction, will
not lead to the eradication of the tumorigenic potential of the
tumor, as that is restricted to the CSC population. Here we
demonstrate that the Nodal/Activin pathway is essential for the
self-renewal capacity and stemness properties of pancreatic
CSCs. Nodal/Activin is strongly expressed in pancreatic CSCs,
but is also expressed by PSCs, which are abundantly present
in the stroma surrounding pancreatic cancer cells andmay serve
as a CSC niche.
In a large set of primary cells and (fresh) primary patient
tissues, we then showed that the CSC compartment is severely
affected by inhibition of this pathway by making use of three
different approaches: first, by using a small molecule inhibitor
(SB431542) targeting the Nodal/Activin receptor Alk4; second,l Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Inc. 441
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Figure 7. In Vivo Effects of Nodal/Activin Inhibition on Established Pancreatic Cancers
(A) Experimental setup for in vivo experiments using L3.6pl cells.
(B) Tumor take-rate (upper left panel), tumor size (lower panel), and representative MRI pictures (right panel) of treated pancreatic cancers.
(C) Kaplan-Meier analysis depicting cumulative survival of respective treatment groups; data are mean ± SEM, nR 3.
(D) Experimental setup for in vivo experiments using primary human pancreatic cancer tissue.
(E) Tumor growth is depicted for the respective treatment groups. Data are mean ± SEM, nR 3.
(F) Histological evaluation on day 100 using cytokeratin 19 staining for gemcitabine alone (GEM) and triple-treated tumors as indicated.
(G) On day 100, tumors from the different groups were digested and analyzed for their respective sphere formation capacity (left panel) and cell surface marker
expression (right panel); data are mean ± SEM, nR 3.
See also Figures S5–S7.
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inhibitor; and third, by genetic knockdown of Nodal, Alk4, and
Smad4 using shRNA technology. Our findings are in line with442 Cell Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Incearlier observations that have identified other developmental
pathways such asmTOR, hedgehog, Notch, and BMP for target-
ing CSCs (Bar et al., 2007; Li et al., 2007; Mueller et al., 2009;.
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Nodal Signaling Drives Cancer Stem CellsPiccirillo and Vescovi, 2006), although their targeting may be of
limited clinical use for at least some of them due to normal
stem-cell-related side effects. Intriguingly, an important feature
of the herein described Nodal/Activin pathway is its complete
lack of activity in normal pancreas and other adult tissue (Top-
czewska et al., 2006), spurring the hope for little to no side effects
because normal stem cells will most likely be spared.
Nodal and Activin are involved in developmental biology by
perpetuating the undifferentiated state of ESCs (Vallier et al.,
2005; Xiao et al., 2006). While the expression of Activin and
the Nodal coreceptor Cripto-1 have previously been demon-
strated in pancreatic cancers (Friess et al., 1994; Kleeff et al.,
1998), we here provide evidence that Nodal, the second ligand
of the Alk4/7 receptor, is expressed in this malignancy, but not
in normal pancreas. Most importantly, Nodal is capable of
strongly propagating the tumorigenic CSC subpopulation as
demonstrated by its pharmacological inhibition using the extra-
cellular Nodal antagonist Lefty and shRNA technology, whereas
Activin was less drastically enriched in pancreatic CSCs and
showed limited effects on their self-renewal capacity in some
tumors. These data are in line with previous reports showing
that Nodal is crucial for tumorigenicity in melanoma and breast
cancer cells, with an embryonic microenvironment reducing
tumorigenic activity and inducing the expression of epithelial
markers by the secretion of Lefty (Postovit et al., 2008; Top-
czewska et al., 2006).
On the other hand, Activin reportedly contributes to an invasive
phenotype in esophageal carcinoma, another epithelial malig-
nancy (Yoshinaga et al., 2004, 2008). In a previous report on the
dynamic regulation of the invasive phenotype of breast cancer
cell lines, the interconversion from noninvasive epithelial-like
CD44+CD24+ cells to invasive mesenchymal CD44+CD24
progeny was also found to be Nodal/Activin dependent (Meyer
et al., 2009). Consistently, we now provide evidence that Activin
alsopromotes invasionof pancreaticCSCsasdoesNodal. These
data have important implications because they indicate that ther-
apeutic strategies should not focus on either Nodal or Activin, but
rather focus on Alk4/7 as their common receptor. Indeed,
a comprehensive set of experiments proves that targeting this
pathwaybyblocking theAlk4/7 receptor using the smallmolecule
inhibitor SB431542 and shRNA technology has a strong impact
on both theCD133+ fraction that is enriched for CSCs and sphere
formation capacity.
Next, we identified human PSCs as an important component
of the stroma that also strongly expresses Nodal/Activin. Condi-
tioned medium from PSCs promoted self-renewal and invasive-
ness of pancreatic CSCs. PSCs, which reside in exocrine areas
of the pancreas, are myofibroblast-like cells known to be acti-
vated upon insult. These cells are analogous to hepatic stellate
cells, with which they share 99% identity at the transcriptome
level (Omary et al., 2007). PSCs are important mediators in the
pancreatic response to injury because they migrate to the
damaged location and promote cell proliferation, migration,
and assembly (Shimizu, 2008). Therefore, because our data
suggest that PSCs may represent an in vivo niche for CSCs,
targeting these interactions could be of pivotal importance for
the development of more effective therapies for pancreatic
cancer. While targeting Alk4/7 as the common receptor for
Nodal/Activin should abrogate autocrine and paracrineCelsignaling, directly eliminating this paracrine source for Nodal/Ac-
tivin may provide additional therapeutic benefits. Intriguingly,
this can be achieved by targeting the hedgehog pathway as
a crucial signaling component for PSCs (Bailey et al., 2008;
Shinozaki et al., 2008), and may account, at least in part, for
the striking therapeutic effects generated by the addition of a
smoothened inhibitor to our armamentarium for treating primary
pancreatic cancer tissue in our studies.
However, translating our findings into the in vivo setting was
not only challenged by alternative sources for Nodal/Activin,
but also by the fact that the Nodal/Activin small molecule inhib-
itor SB431542 as a single therapy was not sufficient to irrevers-
ibly eliminate the cells’ ability to form tumors in vivo. This lack of
in vivo translation of the apparently encouraging in vitro effects
could be explained by the enhanced plasticity of pancreatic
cancer cells. Indeed, after withdrawal of SB431542 and
continued culture of the cells, a drastic rebound of the CD133+
population was also observed in vitro, which retrospectively
rationalizes the still-preserved in vivo tumorigenicity of the cells.
However, the rebound of CD133+ CSCs upon withdrawal was
prevented by addition of gemcitabine to the treatment regimen.
Further mechanistic studies revealed that SB431542 alone
(reversibly) drives CSCs into a more differentiated state, as
evidenced by loss of CD133, but cells still retain the ability to
revert to the CSC phenotype. Intriguingly, although gemcitabine
alone led to a relative enrichment of CSCs, the combination of
SB431542 and gemcitabine resulted in their irreversible and
complete elimination. Indeed, in vitro combination therapy
resulted in complete abrogation of the in vivo tumorigenic poten-
tial of the remaining cells.
This chemosensitizing effect of SB431542 should be of great
therapeutic value for patients with pancreatic cancer and was
therefore further evaluated in vivo. However, testing this treat-
ment regimen in mouse models of pancreatic cancer came
with another caveat. Our first in vivo experiments in established
pancreatic cancer, which were based on the orthotopic implan-
tation of isolated pancreatic cancer cells, confirmed the in vitro
data by illustrating robust therapeutic efficacy and 100%survival
at 100 day follow-up for SB431542 plus gemcitabine. Surpris-
ingly, however, when we thenmoved to a preclinical model using
xenografted primary human pancreatic cancer tissue, tumor
development remained virtually unaffected by this combination.
It is important to note that xenografted pancreatic cancer tissues
contain large amounts of stroma whereas implantation of cancer
cells regularly lacks this important feature. Tumor-associated
stroma does not only provide an additional source for Nodal/Ac-
tivin as described above, but is also capable ofmodulating tumor
vascularization, which could interfere with drug delivery to
cancer (stem) cells. Indeed, impaired drug delivery has already
been demonstrated for pancreatic cancer in a recent landmark
study using a genetically engineered mouse model (Olive et al.,
2009).
Therefore, breaching the ‘‘stroma fortress’’ of pancreatic
cancer represents an important challenge for drug delivery in
general (Neesse et al., 2010) and CSC-targeted therapies in
particular because these cells have been proposed to preferably
reside in hypoxic niches (Borovski et al., 2011; Heddleston et al.,
2009). Intriguingly, when we coadministered the hedgehog
pathway inhibitor CUR199691 (Mueller et al., 2009) to depletel Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier Inc. 443
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a 10-fold increase in drug delivery into the tumor tissue. The
addition of gemcitabine then translated into rapid disease stabi-
lization, and none of the mice required sacrificing during the
100 day study period. Failure to completely eradicate the re-
maining small tumors can be rationalized by the lack of response
of nonproliferating tumor cells to gemcitabine. Most importantly,
however, these small lesions no longer contain CSCs; cells iso-
lated from these remnant tumors did not form spheres anymore.
In contrast, all mice treated with gemcitabine alone had to be
sacrificed within 100 days due to excessive tumor growth. Cells
isolated from these tumors bear strong sphere forming capacity.
Therefore, our data demonstrate the successful combination of
stroma- and CSC-targeting strategies for effectively treating
pancreatic cancer in most relevant preclinical models.
Canonical downstream signaling of Alk4/7 is mediated by
Smad2/3 as well as the Co-Smad Smad4, which is shared by
all TGF-b family members. Importantly, about 50% of patients
with pancreatic cancer bear inactivating mutations or deletions
of the Smad4 gene, which could result in dysfunction of the
pathway (Schneider and Schmid, 2003). While noncanonical
TGF-b family signaling pathways have been described and may
account for the enhanced TGF-b1-induced invasiveness of
pancreatic CSCs (Zhang, 2009), we found that Smad4 knock-
down in previously Smad4-competent cells resulted in reduced
in vivo tumorigenicity, most likely via inhibition of Nodal/Activin
signaling, because these cells no longer responded to the Alk4/7
inhibitor SB431542. Therefore, becauseSmad4seems indispens-
able for the Nodal/Activin signaling cascade, tumors carrying
functionally relevant Smad4 mutations or deletions may not
respond to a Nodal/Activin-targeting therapy. Importantly,
however, not all Smad4mutations actually result in dysfunctional
Smad4; we have identified several tumors bearing Smad4muta-
tions that still demonstrate a functional Smad2/3 cascade,
including asubsequent translocationof pSmad2 into thenucleus,
and that respond to this triple therapy. Future studies will have to
address the question of which patients will most likely respond to
this treatment modality and how best to identify them.EXPERIMENTAL PROCEDURES
Primary Human Pancreatic Cancer Cells
Human pancreatic tumors were obtained with written informed consent from
all patients. For in vitro studies, tissue fragments were minced, enzymatically
digested with collagenase (Stem Cell Technologies, Vancouver, BC) for
60 min at 37C (Mueller et al., 2009), and, after centrifugation for 5 min at
1200 rpm, resuspended as pellets and cultured in RPMI, 10% FBS, and 50
units/ml penicillin/streptomycin.
Pancreatic cancer spheres were generated and expanded in DMEM:F12
(Invitrogen, Karlsruhe, Germany) supplemented with B-27 (GIBCO, Karlsruhe,
Germany) and bFGF (PeproTech EC, London, UK). Ten thousand cells per milli-
liter were seeded in ultra-low attachment plates (Corning B.V., Schiphol-Rijk,
Netherlands) as described previously (Gallmeier et al., 2011). After 7 days of
incubation, sphereswere typically>75mmlargewith97%CD133high. For serial
passaging, 7-day-old spheres were harvested using 40 mmcell strainers, disso-
ciated to single cells with trypsin, and then regrown for 7 days. Cultures were
kept no longer than 4 weeks after recovery from frozen stocks (passage 3–4).Human Pancreatic Cancer Cell Lines
The human pancreatic cancer cell lines L3.6pl, Panc1, and MiaPaCa2 were
maintained as previously described (Hermann et al., 2007).444 Cell Stem Cell 9, 433–446, November 4, 2011 ª2011 Elsevier IncIn Vivo Treatment of Established Pancreatic Cancers
Single-cell suspensions were either orthotopically implanted into the pancreas
of female nude mice (Harlan Europe), or 2 mm3 pieces of primary, in vivo
expanded pancreatic cancer tissue were subcutaneously implanted and
mice were randomized to the respective treatment groups. Size and weight
of the pancreatic tumors were monitored. Gemcitabine was administered
twice a week (125 mg/kg i.p.). SB431542 was used at 25 mg/kg, and
CUR199691, at 100 mg/kg, both by oral gavages twice daily for 3 weeks.
Cytometry
To identify pancreatic CSCs, the following antibodies were used: anti-CD133/
1-APC or PE (Miltenyi, Bergisch-Gladbach, Germany); anti-CXCR4-APC, anti-
SSEA-4-FITC, SSEA-1-APC, EpCAM-FITC, and CD44-PE (all from Beckton
Dickinson, Heidelberg, Germany); and anti-Alk4, anti-Alk5, and anti-Cripto-
1-PE (all fromCell Signaling Technology, Inc.); or appropriate isotype-matched
control antibodies. CD133/2-APC (Miltenyi) was used for purity testing after
MACS. Propidium iodide, 7-AAD, or DAPI was used for exclusion of dead cells
(eBiosciences, San Diego, CA). Samples were analyzed by flow cytometry
using a FACS Canto II (BD) and data were analyzed with FlowJo 9.2 software
(Ashland, OR).
Immunofluorescence
Primary pancreatic cancer cells and spheres were seeded in 96-well dishes
(Corning, NY) and incubated at 37C for 3 hr. Cells were washed with cold
PBS and then fixed with prechilled 4% PFA for 20 min at room temperature.
After blocking with 1% bovine serum albumin in PBS-Triton 0.1%, cells
were incubated with primary antibodies: Nodal (ab556676; Abcam, Inc.),
pSmad2 (3108; Cell Signaling), and EpCAM (BD) overnight at 4C in the
dark. Then cells were washed three timeswith PBS-Triton 0.1%and incubated
with Alexa-Fluor-conjugated secondary antibodies against mouse or rabbit
(Invitrogen) at room temperature for 1 hr in the dark. Cells were mounted in
Vectashield containing DAPI (Vector Laboratories, Burlingame, CA) and
analyzed using an SP5 confocal microscope (Leica, Heidelberg, Germany).
Western Blot Analysis
PVDF membranes containing electrophoretically separated proteins from
human primary pancreatic cancer cells and spheres were probed with mouse
antibodies against Oct4a (2890), Smad2 (3103; both Cell Signaling Tech-
nology), Nanog (ab21624), Nodal (ab556676), GAPDH (ab8245-100; all Ab-
cam), Smad4 (sc-7966; Santa Cruz Biotech), or rabbit antibody against
pSmad2 (3108; Cell Signaling), treated with peroxidase-conjugated goat
anti-mouse or anti-rabbit Ig secondary antibody (Sigma), and then visualized
by enhanced chemiluminescence (Amersham).
Smad2 Phosphorylation Assay
Human primary sphere-derived single cells were grown for 3 hr in DMEM:F12
(GIBCO) without bFGF and B27. Following starvation, cells were incubated for
30min at 37Cwith recombinant human rNodal, Activin, or TGFb1 (R&D) either
alone or in the presence of SB431542 (Sigma) or LY2157299 (AxonMedChem,
Groningen, Netherlands. Anti-Smad2 and anti-phospho-Smad2 (Ser465/467,
Cell Signaling) antibodies were used following themanufacturer’s instructions.
RNA Preparation and Real-Time PCR
Total RNAs from human primary pancreatic cancer cells and spheres were ex-
tracted with TRIzol kit (Life Technologies Inc.) according to the manufacturer’s
instructions. One microgram of total RNA was used for cDNA synthesis with
SuperScript II reverse transcriptase (Life Technologies Inc.) and random
hexamers. Quantitative real-time PCR was performed using SYBR Green
PCR master mix (QIAGEN), according to the manufacturer’s instructions.
The list of utilized primers is depicted in Table S1.
Invasion and Migration Assays
Invasion assays were performed using modified Boyden chambers filled with
Matrigel (BioCoat, BD Biosciences, Heidelberg, Germany). Cells were pre-
treated with SB431542, SB505124, LY2157299, TGF-b receptor II neutralizing
antibodies, or recombinant human Lefty for 1 hr. Five hundred microliters of
cell suspensions containing 53 104 pretreated or untreated cells were added
to the Matrigel-coated inserts, and seven hundred and fifty microliters of.
Cell Stem Cell
Nodal Signaling Drives Cancer Stem Cellsserum-free medium with or without recombinant human Nodal, recombinant
human Activin, or recombinant human TGF-b1 were added to the lower
chamber. The assay chambers were incubated for 22 hr at 37C. Invaded cells
were fixed in 4% PFA and stained with DAPI. The ratio of cells in the lower
chamber versus total seeded cells was calculated.
Lentiviral shRNA Delivery
As lentiviral shuttle backbone we used a pLVX shRNA2 plasmid (Clontech).
shRNA constructs were generated by hybridization in solution of HPLC-puri-
fied paired oligonucleotides with the recessed restriction sites (BamHI and
EcoRI) added to the sequence for cloning purposes. As control we used
pLVX-shRNA expression vectors encoding a scrambled shRNA sequence
with no target (in silico prediction). The shRNA sequences were selected
from the RNAi Consortium website (www.broadinstitute.org/rnai/public). The
inserts of shRNA were annealed from sense and antisense oligonucleotides
with the sequences as provided in Table S2. Lentivirus production and titration
were carried out as previously described (Torres et al., 2011) and regularly con-
tained 13 107 T.U./ml with a 1:100 T.U./physical particles ratio as quantitated
by qPCR. Cells were then transduced with lentiviral stocks diluted to an M.O.I.
of 50 in the presence of polybrene (8 mg/ml, Sigma). A6L and 185 cells were
seeded at a density of 5 3 104 cells per 24 multiwell plate and allowed to
adhere overnight. The next day, cells were infected with the lentivirus for
6 hr. Stably transduced cells were obtained after cell sorting for GFP included
in the viral vector (for Alk4, Alk5, Nodal) or using puromycin resistance
(Smad4). For the transduction with the Nanog promoter reporter, we used
a human Nanog-RFP construct with a zeomycin resistance marker for System
Biosciences (SBI; Mountain View, CA).
MRI
Mice were analyzed with a 3-Tesla MRI system (Magnetom Tim Trio, Siemens,
Erlangen, Germany) using a dedicated small animal coil and T2-weighted
scanning.
Statistical Analyses
Results for continuous variables are presented as means ± standard deviation
(SD) unless stated otherwise. Treatment groups were compared with the inde-
pendent samples t test. Pair-wise multiple comparisons were performed with
the one-way ANOVA (two-sided) with Bonferroni adjustment. p < 0.05 was
considered statistically significant. All analyses were performed using SPSS
17.0 (SPSS Inc., Chicago, Illinois).SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes two tables and seven figures
and can be found with this article online at doi:10.1016/j.stem.2011.10.001.
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